Brandon Couillard
Stock Analyst at Wells Fargo
(4.13)
# 525
Out of 4,996 analysts
145
Total ratings
53.76%
Success rate
13.35%
Average return
Main Sectors:
Stocks Rated by Brandon Couillard
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NTRA Natera | Initiates: Equal-Weight | $175 | $162.97 | +7.38% | 1 | Sep 22, 2025 | |
| GH Guardant Health | Initiates: Overweight | $72 | $60.03 | +19.94% | 1 | Sep 22, 2025 | |
| A Agilent Technologies | Maintains: Overweight | $140 → $150 | $123.39 | +21.57% | 24 | Sep 15, 2025 | |
| CDNA CareDx | Maintains: Equal-Weight | $19 → $14 | $14.94 | -6.29% | 3 | Aug 8, 2025 | |
| MLAB Mesa Laboratories | Upgrades: Equal-Weight | $100 → $67 | $64.51 | +3.86% | 3 | Aug 8, 2025 | |
| WAT Waters | Maintains: Equal-Weight | $330 → $315 | $291.71 | +7.98% | 5 | Aug 5, 2025 | |
| BRKR Bruker | Maintains: Overweight | $60 → $50 | $31.04 | +61.08% | 5 | Aug 5, 2025 | |
| AVTR Avantor | Maintains: Overweight | $19 → $16 | $11.84 | +35.14% | 5 | Aug 4, 2025 | |
| BIO Bio-Rad Laboratories | Maintains: Equal-Weight | $245 → $265 | $271.36 | -2.34% | 12 | Aug 1, 2025 | |
| BIO.B Bio-Rad Laboratories | Maintains: Equal-Weight | $245 → $265 | $269.90 | -1.82% | 12 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $180 → $175 | $125.61 | +39.32% | 2 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $78 → $95 | $117.21 | -18.95% | 4 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $570 → $565 | $464.24 | +21.70% | 6 | Jul 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $210 → $205 | $184.84 | +10.91% | 3 | Jul 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $59 | $51.84 | +13.81% | 1 | May 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $22 → $6 | $7.70 | -22.08% | 2 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1,125 → $1,200 | $1,204.43 | -0.37% | 5 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $130 → $102 | $84.06 | +21.34% | 2 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $285 → $260 | $126.19 | +106.04% | 11 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $77 → $80 | $66.04 | +21.14% | 6 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $85 | $53.57 | +58.67% | 16 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $10 | $2.82 | +254.61% | 1 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $30 → $23 | $20.35 | +13.02% | 1 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $0.83 | +1,472.33% | 1 | Jul 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $3.20 | - | 11 | Nov 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $11 | $2.46 | +347.15% | 2 | Oct 13, 2017 |
Natera
Sep 22, 2025
Initiates: Equal-Weight
Price Target: $175
Current: $162.97
Upside: +7.38%
Guardant Health
Sep 22, 2025
Initiates: Overweight
Price Target: $72
Current: $60.03
Upside: +19.94%
Agilent Technologies
Sep 15, 2025
Maintains: Overweight
Price Target: $140 → $150
Current: $123.39
Upside: +21.57%
CareDx
Aug 8, 2025
Maintains: Equal-Weight
Price Target: $19 → $14
Current: $14.94
Upside: -6.29%
Mesa Laboratories
Aug 8, 2025
Upgrades: Equal-Weight
Price Target: $100 → $67
Current: $64.51
Upside: +3.86%
Waters
Aug 5, 2025
Maintains: Equal-Weight
Price Target: $330 → $315
Current: $291.71
Upside: +7.98%
Bruker
Aug 5, 2025
Maintains: Overweight
Price Target: $60 → $50
Current: $31.04
Upside: +61.08%
Avantor
Aug 4, 2025
Maintains: Overweight
Price Target: $19 → $16
Current: $11.84
Upside: +35.14%
Bio-Rad Laboratories
Aug 1, 2025
Maintains: Equal-Weight
Price Target: $245 → $265
Current: $271.36
Upside: -2.34%
Bio-Rad Laboratories
Aug 1, 2025
Maintains: Equal-Weight
Price Target: $245 → $265
Current: $269.90
Upside: -1.82%
Jul 30, 2025
Maintains: Overweight
Price Target: $180 → $175
Current: $125.61
Upside: +39.32%
Jul 30, 2025
Maintains: Equal-Weight
Price Target: $78 → $95
Current: $117.21
Upside: -18.95%
Jul 24, 2025
Maintains: Overweight
Price Target: $570 → $565
Current: $464.24
Upside: +21.70%
Jul 23, 2025
Maintains: Equal-Weight
Price Target: $210 → $205
Current: $184.84
Upside: +10.91%
May 30, 2025
Initiates: Overweight
Price Target: $59
Current: $51.84
Upside: +13.81%
May 8, 2025
Downgrades: Equal-Weight
Price Target: $22 → $6
Current: $7.70
Upside: -22.08%
May 5, 2025
Maintains: Equal-Weight
Price Target: $1,125 → $1,200
Current: $1,204.43
Upside: -0.37%
Apr 17, 2025
Maintains: Equal-Weight
Price Target: $130 → $102
Current: $84.06
Upside: +21.34%
Jan 23, 2025
Maintains: Buy
Price Target: $285 → $260
Current: $126.19
Upside: +106.04%
Jan 23, 2025
Maintains: Hold
Price Target: $77 → $80
Current: $66.04
Upside: +21.14%
Nov 6, 2024
Maintains: Buy
Price Target: $84 → $85
Current: $53.57
Upside: +58.67%
Aug 27, 2024
Initiates: Overweight
Price Target: $10
Current: $2.82
Upside: +254.61%
Feb 9, 2024
Downgrades: Hold
Price Target: $30 → $23
Current: $20.35
Upside: +13.02%
Jul 13, 2021
Initiates: Buy
Price Target: $13
Current: $0.83
Upside: +1,472.33%
Nov 2, 2017
Downgrades: Hold
Price Target: n/a
Current: $3.20
Upside: -
Oct 13, 2017
Maintains: Buy
Price Target: $9 → $11
Current: $2.46
Upside: +347.15%